ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Intangible Assets
ExpreS2ion Biotech Holding AB
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Intangible Assets
kr1.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Intangible Assets
kr772k
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Intangible Assets
kr15.1m
|
CAGR 3-Years
22%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Intangible Assets
kr3.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
67%
|
CAGR 10-Years
37%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Intangible Assets
kr40.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
25%
|
|
|
BioArctic AB
STO:BIOA B
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Intangible Assets?
Intangible Assets
1.7m
SEK
Based on the financial report for Sep 30, 2025, ExpreS2ion Biotech Holding AB's Intangible Assets amounts to 1.7m SEK.
What is ExpreS2ion Biotech Holding AB's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-18%
Over the last year, the Intangible Assets growth was -24%. The average annual Intangible Assets growth rates for ExpreS2ion Biotech Holding AB have been -18% over the past three years , -18% over the past five years .
